LON:SNG

Synairgen (SNG) Share Forecast, Price & News

GBX 8.20

-0.30 (-3.53%)

(As of 06/8/2023 ET)

Compare

Today's Range: 7.60
▼
8.58
50-Day Range: 7.43
▼
16.50
52-Week Range: 7.01
▼
36.48

Volume: 539,441 shs
Average Volume: 508,413 shs
Market Capitalization: £16.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About Synairgen (LON:SNG) Stock

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Receive SNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter.

SNG Stock News Headlines

April 30, 2023 | americanbankingnews.com

Synairgen (LON:SNG) Stock Price Passes Below 200-Day Moving Average of $14.31

April 7, 2023 | americanbankingnews.com

Synairgen (LON:SNG) Reaches New 52-Week Low at $7.01

June 8, 2023 | UNKNOWN (Ad)

The Stock That's Brining Lithium Back To America!

The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil

April 7, 2023 | americanbankingnews.com

Synairgen (LON:SNG) Sets New 12-Month Low at $7.01

January 4, 2023 | finance.yahoo.com

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

October 4, 2022 | proactiveinvestors.com

FTSE 100 jumps 140 points as L&G statement reassures - Proactive Investors USA

October 4, 2022 | finance.yahoo.com

Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19

October 4, 2022 | businesswire.com

Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 - Business Wire

June 8, 2023 | UNKNOWN (Ad)

The Stock That's Brining Lithium Back To America!

The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil

September 30, 2022 | marketwatch.com

Synairgen Shares Drop Amid Phase 3 Study Issues; Pretax Loss Narrows - MarketWatch

September 29, 2022 | lse.co.uk

EARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens | Financial News - London South East

September 29, 2022 | proactiveinvestors.com

Tesla appoints Airbnb co-founder Joe Gebbia to board - Proactive Investors USA

September 20, 2022 | finance.yahoo.com

Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

September 20, 2022 | marketscreener.com

Synairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial - Marketscreener.com

September 20, 2022 | proactiveinvestors.com

Synairgen to present data showing drug lowers risk of long Covid symptoms - Proactive Investors USA

September 7, 2022 | lse.co.uk

IN BRIEF: Synairgen shares rise as positive data found for COPD | Financial News - London South East

September 7, 2022 | finance.yahoo.com

Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients

September 7, 2022 | lse.co.uk

Synairgen unveils positive clinical trial data | Financial News - London South East

September 7, 2022 | marketwatch.com

Synairgen Gets Positive Data From Trial of Respiratory Drug Treatment - MarketWatch

September 7, 2022 | proactiveinvestors.com

Synairgen reports positive data from respiratory viral infection drug - Proactive Investors USA

September 5, 2022 | proactiveinvestors.com

FTSE 100 opens lower as oil giants push ahead - Proactive Investors USA

September 5, 2022 | morningstar.co.uk

TRADING UPDATES: Bradda wins drilling approval; Oakley invests in vLex - Morningstar

September 5, 2022 | proactiveinvestors.com

Synairgen to play key role in respiratory viral infection study - Proactive Investors USA

August 5, 2022 | fool.co.uk

The Synairgen share price crashes again as US study is halted

June 29, 2022 | globenewswire.com

Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Insights | DelveInsight - GlobeNewswire

May 31, 2022 | finance.yahoo.com

Can Synairgen (LON:SNG) Afford To Invest In Growth?

May 27, 2022 | morningstar.co.uk

IN BRIEF: Synairgen shares fall as loss widens on higher costs - Morningstar

See More Headlines

SNG Price History

30 days | 90 days | 365 days | Advanced Chart

SNG Company Calendar

Last Earnings: 9/29/2020
Today: 6/08/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:SNG
CUSIP: N/A
CIK: N/A
Web: www.synairgen.com
Phone: +44-23-80512800
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-17,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -61.62%
Return on Assets: -37.22%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 7.19
Quick Ratio: 6.35

Sales & Book Value

Annual Sales: £79,000.00
Price / Sales: 201.38
Cash Flow: GBX 4.16 per share
Price / Cash Flow: 1.90
Book Value: GBX 10 per share
Price / Book: 0.79

Miscellaneous

Outstanding Shares: 201,380,000
Free Float: N/A
Market Cap: £15.91 million
Optionable: Not Optionable
Beta: -2.27

Key Executives

Mr. Richard Marsden (Age 55)
CEO, MD & Exec. Director
Comp: $328k

Prof. Stephen T. Holgate CBE (Age 75)
M.D., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
Comp: $44k

Mr. John Ward (Age 61)
CFO & Exec. Director
Comp: $240k

Dr. Phillip David Monk (Age 54)
Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director
Comp: $240k

Prof. Donna Davies
Co-Founder & Member of Scientific Advisory Board

Prof. Ratko Djukanovic
Co-Founder & Member of Scientific Advisory Board

Ms. Brooke S Clarke
Sr. VP & Head of Communications

Dr. Gareth E. Walters Ph.D. (Age 64)
Chief Regulatory Officer

Ms. Jody Brookes
Sr. VP & Head of Clinical Operations

Mr. Richard Hennings (Age 53)
Chief Commercial Officer

Key Competitors

View All Competitors

SNG Stock - Frequently Asked Questions

How have SNG shares performed in 2023?: Synairgen's stock was trading at GBX 13.50 at the start of the year. Since then, SNG stock has decreased by 41.5% and is now trading at GBX 7.90.
View the best growth stocks for 2023 here.
How were Synairgen's earnings last quarter?: Synairgen plc (LON:SNG) announced its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share for the quarter.
What other stocks do shareholders of Synairgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Synairgen investors own include Alibaba Group (BABA), Yamana Gold (YRI), Eldorado Gold (ELD), Ocado Group (OCDO), Polo Resources (POL), Silvercorp Metals (SVM), W Resources (WRES), Associated British Foods (ABF), Ariana Resources (AAU) and First Majestic Silver (AG).
What is Synairgen's stock symbol?: Synairgen trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

How do I buy shares of Synairgen?: Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Synairgen's stock price today?: One share of SNG stock can currently be purchased for approximately GBX 7.90.
How much money does Synairgen make?: Synairgen (LON:SNG) has a market capitalization of £15.91 million and generates £79,000.00 in revenue each year. The company earns £-17,640,000.00 in net income (profit) each year or GBX (0.08) on an earnings per share basis.
How can I contact Synairgen?: Synairgen's mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The official website for the company is www.synairgen.com. The company can be reached via phone at +44-23-80512800.

This page (LON:SNG) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial